Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as smal… Read more
Market Cap & Net Worth: Halozyme Therapeutics Inc (HALO)
Halozyme Therapeutics Inc (NASDAQ:HALO) has a market capitalization of $7.66 Billion ($7.66 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2056 globally and #1484 in its home market, demonstrating a -4.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Halozyme Therapeutics Inc's stock price $65.13 by its total outstanding shares 117597000 (117.60 Million).
Halozyme Therapeutics Inc Market Cap History: 2015 to 2026
Halozyme Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows growth from $2.04 Billion to $7.66 Billion (15.51% CAGR).
Index Memberships
Halozyme Therapeutics Inc is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$879.22 Billion | 0.86% | #19 of 30 |
|
Dow Jones Biotechnology
DJUSBT
|
$1.15 Trillion | 0.66% | #15 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.34% | #43 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.02% | #264 of 3165 |
|
S&P Midcap 400
MID
|
$3.04 Trillion | 0.29% | #155 of 401 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.49% | #28 of 263 |
Weight: Halozyme Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Halozyme Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Halozyme Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.54x
Halozyme Therapeutics Inc's market cap is 5.54 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
12.66x
Halozyme Therapeutics Inc's market cap is 12.66 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.04 Billion | $135.06 Million | -$32.23 Million | 15.09x | N/A |
| 2016 | $1.16 Billion | $146.69 Million | -$103.02 Million | 7.92x | N/A |
| 2017 | $2.38 Billion | $316.61 Million | $62.97 Million | 7.53x | 37.84x |
| 2018 | $1.72 Billion | $151.86 Million | -$80.33 Million | 11.33x | N/A |
| 2019 | $2.08 Billion | $195.99 Million | -$72.24 Million | 10.64x | N/A |
| 2020 | $5.02 Billion | $267.59 Million | $129.09 Million | 18.77x | 38.91x |
| 2021 | $4.73 Billion | $443.31 Million | $402.71 Million | 10.67x | 11.74x |
| 2022 | $6.69 Billion | $660.12 Million | $202.13 Million | 10.14x | 33.10x |
| 2023 | $4.35 Billion | $829.25 Million | $281.59 Million | 5.24x | 15.43x |
| 2024 | $5.62 Billion | $1.02 Billion | $444.09 Million | 5.54x | 12.66x |
Competitor Companies of HALO by Market Capitalization
Companies near Halozyme Therapeutics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Halozyme Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Halozyme Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Halozyme Therapeutics Inc's market cap moved from $2.04 Billion to $ 7.66 Billion, with a yearly change of 15.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $7.66 Billion | -3.22% |
| 2025 | $7.91 Billion | +40.77% |
| 2024 | $5.62 Billion | +29.36% |
| 2023 | $4.35 Billion | -35.04% |
| 2022 | $6.69 Billion | +41.51% |
| 2021 | $4.73 Billion | -5.85% |
| 2020 | $5.02 Billion | +140.89% |
| 2019 | $2.08 Billion | +21.19% |
| 2018 | $1.72 Billion | -27.79% |
| 2017 | $2.38 Billion | +105.06% |
| 2016 | $1.16 Billion | -42.99% |
| 2015 | $2.04 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Halozyme Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.66 Billion USD |
| MoneyControl | $7.66 Billion USD |
| MarketWatch | $7.66 Billion USD |
| marketcap.company | $7.66 Billion USD |
| Reuters | $7.66 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.